(Q34545093)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14770440%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

title

Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14770440%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

main subject

phase II clinical trial

0 references

author

Karen H. Antman

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14770440%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

2

Cathryn Rankin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14770440%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

author name string

Mark M Zalupski

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14770440%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

James R Ryan

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14770440%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

David R Lucas

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14770440%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

Jeffrey Muler

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14770440%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

Keith S Lanier

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14770440%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

George Thomas Budd

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14770440%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

J Sybil Biermann

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14770440%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

Frederick J Meyers

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14770440%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

language of work or name

English

0 references

publication date

1 February 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14770440%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14770440%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

volume

100

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14770440%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

page(s)

818-825

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14770440%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14770440%20AND%20SRC:MED&resulttype=core&format=json

The therapy of osteogenic sarcoma: Current status and thoughts for the future

18 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20021

7 January 2021

The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20021

7 January 2021

Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20021

7 January 2021

Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20021

7 January 2021

Common musculoskeletal tumors of childhood and adolescence

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20021

7 January 2021

A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20021

7 January 2021

Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20021

7 January 2021

Survival, prognosis, and therapeutic response in osteogenic sarcoma. The memorial hospital experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20021

7 January 2021

Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20021

7 January 2021

Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20021

7 January 2021

Preoperative chemotherapy for osteogenic sarcoma:Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20021

7 January 2021

Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20021

7 January 2021

Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20021

7 January 2021

Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20021

7 January 2021

Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20021

7 January 2021

Influence of Doxorubicin Dose Intensity on Response and Outcome for Patients With Osteogenic Sarcoma and Ewing's Sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20021

7 January 2021

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20021

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20021

7 January 2021

Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20021

7 January 2021

Clinical importance of near-diploid tumor stem lines in patients with osteosarcoma of an extremity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20021

7 January 2021

P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20021

7 January 2021

Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20021

7 January 2021

Expression of HER2/erbB-2 correlates with survival in osteosarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20021

7 January 2021

Prognostic factors in osteosarcoma: a critical review.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20021

7 January 2021

Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20021

7 January 2021

Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20021

7 January 2021

Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20021

7 January 2021

Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20021

7 January 2021

Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20021

7 January 2021

A randomized study comparing high-dose methotrexate with moderate-dose methotrexate as components of adjuvant chemotherapy in childhood nonmetastatic osteosarcoma: a report from the Childrens Cancer Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20021

7 January 2021

Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. European Osteosarcoma Intergroup

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20021

7 January 2021

Identifiers

DOI

10.1002/CNCR.20021

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14770440%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

1 reference